全文获取类型
收费全文 | 22914篇 |
免费 | 2444篇 |
国内免费 | 709篇 |
专业分类
耳鼻咽喉 | 172篇 |
儿科学 | 262篇 |
妇产科学 | 215篇 |
基础医学 | 1042篇 |
口腔科学 | 552篇 |
临床医学 | 3729篇 |
内科学 | 1691篇 |
皮肤病学 | 166篇 |
神经病学 | 821篇 |
特种医学 | 601篇 |
外国民族医学 | 7篇 |
外科学 | 1446篇 |
综合类 | 3389篇 |
现状与发展 | 1篇 |
一般理论 | 1篇 |
预防医学 | 5580篇 |
眼科学 | 116篇 |
药学 | 3467篇 |
78篇 | |
中国医学 | 2115篇 |
肿瘤学 | 616篇 |
出版年
2024年 | 71篇 |
2023年 | 557篇 |
2022年 | 808篇 |
2021年 | 1059篇 |
2020年 | 1188篇 |
2019年 | 944篇 |
2018年 | 886篇 |
2017年 | 940篇 |
2016年 | 1004篇 |
2015年 | 970篇 |
2014年 | 1796篇 |
2013年 | 1970篇 |
2012年 | 1612篇 |
2011年 | 1665篇 |
2010年 | 1258篇 |
2009年 | 1186篇 |
2008年 | 1100篇 |
2007年 | 1068篇 |
2006年 | 941篇 |
2005年 | 739篇 |
2004年 | 634篇 |
2003年 | 542篇 |
2002年 | 408篇 |
2001年 | 375篇 |
2000年 | 306篇 |
1999年 | 296篇 |
1998年 | 223篇 |
1997年 | 176篇 |
1996年 | 159篇 |
1995年 | 146篇 |
1994年 | 157篇 |
1993年 | 111篇 |
1992年 | 119篇 |
1991年 | 89篇 |
1990年 | 79篇 |
1989年 | 68篇 |
1988年 | 61篇 |
1987年 | 41篇 |
1986年 | 51篇 |
1985年 | 57篇 |
1984年 | 46篇 |
1983年 | 22篇 |
1982年 | 28篇 |
1981年 | 20篇 |
1980年 | 29篇 |
1979年 | 10篇 |
1978年 | 16篇 |
1977年 | 13篇 |
1975年 | 7篇 |
1974年 | 6篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
2.
3.
5.
《Value in health》2022,25(6):1018-1029
ObjectivesThis study aimed to explore quality-adjusted life-year (QALY) and subsequent cost-effectiveness estimates based on the more physical health–focused EQ-5D 5-level version (EQ-5D-5L) value set for England or cross-walked EQ-5D 3-level version UK value set scores or more mental health recovery-focused Recovering Quality of Life Utility Index (ReQoL-UI), when using alternative within-trial statistical methods. We describe possible reasons for the different QALY estimates based on the interaction between item scores, health state profiles, preference-based scores, and mathematical and statistical methods chosen.MethodsQALYs are calculated over 8 weeks from a case study 2:1 (intervention:control) randomized controlled trial in patients with anxiety or depression. Complete case and with missing cases imputed using multiple-imputation analyses are conducted, using unadjusted and regression baseline-adjusted QALYs. Cost-effectiveness is judged using incremental cost-effectiveness ratios and acceptability curves. We use previously established psychometric results to reflect on estimated QALYs.ResultsA total of 361 people (241:120) were randomized. EQ-5D-5L crosswalk produced higher incremental QALYs than the value set for England or ReQoL-UI, which produced similar unadjusted QALYs, but contrasting baseline-adjusted QALYs. Probability of cost-effectiveness <£30 000 per QALY ranged from 6% (complete case ReQoL-UI baseline-adjusted QALYs) to 64.3% (multiple-imputation EQ-5D-5L crosswalk unadjusted QALYs). The control arm improved more on average than the intervention arm on the ReQoL-UI, a result not mirrored on the EQ-5D-5L nor condition-specific (Patient-Health Questionnaire-9, depression; Generalized Anxiety Disorder-7, anxiety) measures.ConclusionsReQoL-UI produced contradictory cost-effectiveness results relative to the EQ-5D-5L. The EQ-5D-5L’s better responsiveness and “anxiety/depression” and “usual activities” items drove the incremental QALY results. The ReQoL-UI’s single physical health item and “personal recovery” construct may have influenced its lower 8-week incremental QALY estimates in this patient sample. 相似文献
6.
目的 本实验采用HPLC方法建立来自3个产地15批怀牛膝药材的指纹图谱,并对β-蜕皮甾酮,25R-牛膝甾酮,25S-牛膝甾酮进行含量测定,同时通过化学计量学的方法对15批怀牛膝进行质量评价。方法 选用Waters SunFire C18(150 mm×4.6 mm,5 μm)色谱柱,检测波长280 nm,以乙腈-0.1%甲酸水梯度洗脱,流速为1.0 mL·min-1,柱温25℃,进样量10 μL。以β-蜕皮甾酮峰为参照峰,运用软件《中药色谱指纹图谱相似度评价系统(2012版)》对15批怀牛膝药材进行相似度分析,使用Metabo Analyst 5.0网站进行聚类热图分析,使用SIMCA 14.1软件进行PCA和PLS-DA分析。结果 标定了31个共有指纹峰,指认了3个已知成分,并对其进行含量测定,化学计量学分析结果将15批怀牛膝药材样品分为3类,并且筛选了不同产地间潜在的差异性成分。结论 该方法具有良好的精密度、重复性以及稳定性,可为怀牛膝的质量评价与控制提供科学依据及参考。 相似文献
7.
Objective
The aim of the study was to estimate the effect of the state-based reinsurance programs through the section 1332 State Innovation Waivers on health insurance marketplace premiums and insurer participation.Data Source
2015 to 2022 Robert Wood Johnson Foundation Health Insurance Exchange Compare Datasets.Study Design
An event study difference-in-differences (DD) model separately for each year of implementation and a synthetic control method (SCM) are used to estimate year-by-year effects following program implementation.Data Collection/Extraction Methods
Not applicable.Principal Findings
Reinsurance programs were associated with a decline in premiums in the first year of implementation by 10%–13%, 5%–19%, and 11%–17% for bronze, silver, and gold plans (p < 0.05). There is a trend of sustained declines especially for states that implemented their programs in 2019 and 2020. The SCM analyses suggest some effect heterogeneity across states but also premium declines across most states. There is no evidence that reinsurance programs affected insurer participation.Conclusion
State-based reinsurance programs have the potential to improve the affordability of health insurance coverage. However, reinsurance programs do not appear to have had an effect on insurer participation, highlighting the need for policy makers to consider complementary strategies to encourage insurer participation. 相似文献8.
9.
《Research in social & administrative pharmacy》2022,18(3):2367-2391
ObjectivesSeveral implementation strategies can reduce potentially inappropriate medication (PIM) prescribing. Although use of PIMs has declined in recent years, it remains prevalent. Various strategies exist to improve the appropriateness of medication use. However, little is known about the processes of these different implementation strategies. This scoping review aims to investigate how the process evaluation of implementation strategies for reducing PIM prescribing in the older population has been studied.MethodsWe searched for process evaluations of implementation strategies for reducing PIM prescribing in PUBMED, SCOPUS and Web of Science published between January 2000 and November 2019 in English. We applied the following inclusion criteria: patients aged ≥65 years, validated PIM criteria, and implementation process evaluated. The review focuses on decision support for health care professionals. We described the findings of the process evaluations, and compared the authors’ concepts of process evaluation of the included publications to those of Proctor et al.( 2010).ResultOf 9131 publications screened, 29 met our inclusion criteria. Different process evaluation conceptualizations were identified. Most process evaluations took place in the initial stages of the process (acceptability, adoption, appropriateness, and feasibility) and sustainability and implementation costs were seldom evaluated. None of the included publications evaluated fidelity.Multifaceted interventions were the most studied implementation strategies. Medication review was more common in acceptability evaluations, multidisciplinary interventions in adoption evaluations, and computerized systems and educational interventions in feasibility evaluations. Process evaluations were studied from the health care professionals’ viewpoint in most of the included publications, but the management viewpoint was missing.DiscussionThe conceptualization of process evaluation in the field of PIM prescribing is indeterminate. There is also a current gap in the knowledge of sustainability and implementation costs. Clarifying the conceptualization of implementation process evaluation is essential in order to effectively translate research knowledge into practice. 相似文献
10.
《Vaccine》2022,40(30):3999-4007
BackgroundA value of vaccination framework for economic evaluation (EE) identified unique value concepts for the broad benefits vaccination provides to individuals, society, healthcare systems and national economies. The objectives of this paper were to work with experts in developed countries to objectively identify three priority concepts to extend current EE.MethodsThe previously developed classification of value concepts in vaccination distinguished 18 concepts, categorised as conventional payer and societal perspective concepts and novel broader societal concepts. Their inclusion in current EE guidelines was assessed. Experts identified eight criteria relevant to decision-making and measurement feasibility, which were weighted and used to score each concept. The relative ranking of concepts by importance and the gaps in guidelines were used to identify three priority concepts on which to focus immediate efforts to extend EE.ResultsThe EE guidelines review highlighted differences across countries and between guidelines and practice. Conventional payer perspective concepts (e.g., individual and societal health gains and medical costs) were generally included, while gaps were evident for conventional societal perspective concepts (e.g., family/caregiver health and economic gains). Few novel broader societal benefits were considered, and only in ad hoc cases. The top-three concepts for near-term consideration: macroeconomic gains (e.g., benefiting the economy, tourism), social equity and ethics (e.g., equal distribution of health outcomes, reduced health/financial equity gaps) and health systems strengthening, resilience and security (e.g., efficiency gains, reduced disruption, increased capacity).ConclusionsGaps, inconsistencies and limited assessment of vaccination value in EE can lead to differences in policy and vaccination access. The three priority concepts identified provide a feasible approach for capturing VoV more broadly in the near-term. Robust methods for measuring and valuing these concepts in future assessments will help strengthen the evidence used to inform decisions, improving access to vaccines that are demonstrably good value for money from society’s point of view. 相似文献